In the 90 days prior to the date of this filing, there have been 18 insider transactions reported to the SEC for Aimmune Therapeutics. These transactions came from the activities of 5 individual insiders that resulted in a net acquisition of 54,245 company shares. This compares with the preceding 90-day window of time where there were 2 transactions from 1 insider and resulted in no net change in insider holdings.
This level of insider transactions is lower than the peer group average in the 22-company Proprietary & Advanced Pharmaceuticals peer group over the last 90-day period. Activity in the peer group averaged 52.7 transactions per company, with company insiders acquiring on average 91,246 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1631650/000089924320009016/xslF345X03/doc4.xml
|Insider Trends: Insider Sales Add to 90-Day Trend at...|
|BioSig Technologies Wins Additional Patent for its F...|
|Insider Trends: 90-Day Insider Selling Trend Prolong...|
|US Rail Traffic Falls 17% in Week Ended May 30 as 11...|
|Research Alert: CFRA Lowers Opinion On Entegris To S...|